税收优惠对我国生物医药企业创新绩效的影响效应研究

Research on the Impact of Tax Incentives on Innovation Performance of Biomedical enterprises in China

本文基于2016—2021年我国生物医药行业上市公司财务数据,通过构建回归模型,探究税收优惠对生物医药企业创新绩效的作用效果,并从产权性质和中介效应等方面进行分层分类的深入探究,研究发现:税收优惠对生物医药行业的创新绩效,包括创新数量和创新质量都具有显著正向促进作用;无论是在创新数量方面,还是在创新质量方面,非国有企业相对于国有企业对税收优惠更加敏感;生物医药企业的研发投入水平在税收优惠对创新绩效的影响效应中起到中介作用。基于以上研究结果,提出税收优惠体系化建设等政策建议。

Based on the financial data of listed biomedical companies in China from 2016 to 2021,this paper explores the effect of tax incentives on the innovation performance of biomedical enterprises by constructing a regression model,and it further explores the hierarchical classification from the property rights and intermediary effects,so as to put forward more accurate policy suggestions.The results show that firstly,tax incentives have a significant positive effect on both the innovation quantity and high-quality innovation performance of the biomedical industry.Secondly,in terms of the innovation quantity or high-quality innovation performance,non-state-owned enterprises are more sensitive to tax incentives than state-owned enterprises.Thirdly,the mediating effect test results show that the R&D investment level of biomedical enterprises plays a mediating role in the effect of tax incentives on innovation performance.